The short answer
A liquid biopsy looks for tumor DNA fragments in blood. It is useful when tissue is limited, but a negative result does not rule out a mutation, so tissue testing may still be needed.
Tumors shed small fragments of DNA into the bloodstream. A liquid biopsy sequences those fragments from an ordinary blood draw.
The strongest current use is finding targetable mutations quickly when tissue is insufficient, when a biopsy would be risky, or when a result is needed sooner than a procedure allows.
A negative result is not a reliable all-clear. Tumors that shed little DNA — small ones, brain tumors behind the blood-brain barrier, some slow-growing types — can carry a mutation the blood test never sees.
Because of this, guidance generally supports tissue testing when a liquid biopsy is negative and a targetable mutation is still plausible.
Choose how you want to understand this
The full explanation.
What is being measured
Cells throughout your body die all the time. As they die, they release fragments of their DNA into the bloodstream. Most of that free-floating DNA comes from normal cells. When a tumor is present, some of it comes from the tumor. That portion is circulating tumor DNA, or ctDNA.
A liquid biopsy is a blood draw that captures this free DNA and sequences it. It looks for the genetic changes that identify cancer. More usefully, it looks for the ones that a drug can target. Despite the name, nothing is cut and nothing is removed.
Where it genuinely helps
When there is not enough tissue. A small needle biopsy may bring back too few cells for a full genomic panel. Rather than repeat the procedure, doctors can often get the answer from blood.
When a biopsy would be difficult or risky. A lesion may sit somewhere awkward. Or your general condition may make a procedure unwise.
When speed matters. Blood results often come back faster than arranging a biopsy, processing the tissue and sequencing it. In advanced lung cancer, a targetable mutation changes the whole first-line treatment. That time can matter.
When the cancer has changed. A tumor that has grown despite treatment may have picked up new resistance mutations. Those were not in the original biopsy. Blood samples the cancer as it is now. It also draws from several sites at once, rather than one spot. Studies presented to ASCO found resistance mutations in blood that were absent from the original tissue in around a quarter of patients.
The limitation that matters most
A negative liquid biopsy does not mean a mutation is absent. It may mean the tumor is not shedding enough DNA for the test to see it.
Shedding varies enormously. Small tumors shed little. Brain tumors shed poorly into blood, because of the blood-brain barrier. Some tissue types and some body sites release far less than others.
The tumor fraction is the share of your cell-free DNA that came from the tumor. It can be a fraction of a percent. Below a certain level, the test can no longer call anything reliably. Some laboratories now report the tumor fraction, precisely so clinicians can judge how much weight a negative result deserves.
The practical rule follows from that. Suppose a liquid biopsy is negative, a targetable mutation is still plausible, and finding it would change treatment. Then tissue testing is the recommended next step. Many teams work this way on purpose. Blood first, because it is fast and non-invasive. Tissue afterwards, if the blood tells them nothing.
False positives happen too
Not every mutation found in plasma came from a tumor. With age, blood-forming stem cells pick up mutations. They then produce growing groups of blood cells that carry those mutations. This is called clonal hematopoiesis. Those cells shed DNA as well. Genes such as TP53, DNMT3A, TET2, ATM and CHEK2 are common sites. A result in one of these genes may reflect your bone marrow rather than your cancer. Laboratories flag this more and more often. Sequencing white blood cells alongside plasma helps tell the two apart.
Occasionally a liquid biopsy also turns up a change that was inherited, rather than picked up during life. That opens a separate conversation about germline testing and what it means for your family.
The emerging use: minimal residual disease
The most active area of development uses ctDNA after treatment. The aim is to detect cancer that remains but is too small to see on any scan. Detectable ctDNA after surgery is consistently linked to a higher risk of recurrence. The evidence is furthest along in colorectal cancer. There, trials have tested whether ctDNA results can decide who needs chemotherapy after surgery.
This is genuinely promising, and genuinely unfinished. Knowing that a test predicts recurrence is not the same as knowing that acting on it earlier helps people live longer or better. Outside specific settings and clinical trials, most teams will not change treatment on an MRD result alone.
What to ask when a liquid biopsy is ordered
The useful questions are about purpose and consequence. What decision will this result inform? What happens if it comes back negative? Will tissue be tested as well? A liquid biopsy is a fast, low-burden test with a specific blind spot. Knowing where that blind spot sits is what makes the result usable.
Sources
Words to know
Tap any term to see what it means.
Common questions
Is a liquid biopsy as good as a tissue biopsy?
For finding a mutation that is present, they agree closely much of the time, and agreement is highest when the blood and tissue samples were taken close together. Where they differ is in what a negative result means. Tissue tells you a mutation is absent from the piece examined; blood may simply have failed to capture DNA that was never shed in sufficient quantity.
My liquid biopsy found nothing. What happens now?
If a targetable mutation would change your treatment and one is still plausible, the usual next step is tissue testing — either on an existing block or from a new biopsy. A common approach is to test blood first because it is fast and non-invasive, then confirm on tissue if the blood is uninformative.
What is clonal hematopoiesis and why does it matter?
As people age, blood-forming stem cells acquire mutations and produce populations of blood cells carrying them. Those cells shed DNA into plasma just as tumors do. A liquid biopsy can pick up such a mutation and attribute it to cancer when it came from bone marrow. Good laboratories flag likely clonal hematopoiesis, and sequencing white blood cells alongside plasma helps distinguish the two.
Can a ctDNA test tell me whether my cancer has come back?
In some situations it can detect residual or returning disease earlier than scans. This is the minimal residual disease application, and evidence is strongest so far in colorectal cancer. Whether acting on that early signal improves outcomes is still being tested in trials, which is why many teams will not change treatment on a ctDNA result alone outside a study.
Is a liquid biopsy the same as a tumor marker test?
No. Tumor markers measure a protein level. A liquid biopsy sequences DNA and reports specific genetic changes. They answer different questions and are used at different points in care.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Written by: Cancer ExplainedSources last checked: 2026-07-30 what this meansLast updated: 2026-08-10Next planned review: 2027-07-30
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source checked. This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
General education — varies by person. Answers genuinely differ between people. This page explains what commonly varies and points you to your care team for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source checked — This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
Still have questions?
Educational answers, plain language
Free to print and share